Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 11/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | GLA | P06280 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3171735 | 0.84 | TAAR1 (0.73) | TAAR1TSHRCYP2D6LMNAGLA | |
| SCHEMBL3166234 | 0.84 | TAAR1 (0.71) | TAAR1TSHRCYP2D6LMNAGLA | |
| SCHEMBL3164174 | 0.84 | TAAR1 (0.71) | TAAR1TSHRCYP2D6LMNAGLA | |
| SCHEMBL3155837 | 0.84 | TSHR (1.00) | TAAR1TSHRCYP2D6LMNAGLA | |
| SCHEMBL3164851 | 0.84 | TAAR1 (0.72) | TAAR1TSHRCYP2D6LMNAGLA | |
| SCHEMBL3162344 | 0.83 | TAAR1 (0.71) | TAAR1TSHRCYP2D6LMNAGLA | |
| SCHEMBL3164555 | 0.83 | TAAR1 (0.70) | TAAR1TSHRCYP2D6LMNAGLA | |
| SCHEMBL3155735 | 0.83 | TAAR1 (0.70) | TAAR1TSHRCYP2D6LMNAGLA | |
| SCHEMBL3155867 | 0.83 | TAAR1 (0.70) | TAAR1TSHRCYP2D6LMNAGLA | |
| SCHEMBL3162998 | 0.82 | TAAR1 (0.69) | TAAR1TSHRCYP2D6LMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101528709-B | Aminomethyl-2-imidazoles with affinity with the trace amine associated receptors | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-01 | — | — | CN | claimed |
| EP-2076496-B1 | AMINOMETHYL-2-IMIDAZOLES WITH AFFINITY WITH THE TRACE AMINE ASSOCIATED RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-03-31 | — | — | EP | claimed |
| CN-101528709-A | Aminomethyl-2-imidazoles with affinity with the trace amine associated receptors | HOFFMANN LA ROCHE (CH) | 2009-09-09 | — | — | CN | claimed |
| EP-2076496-A1 | AMINOMETHYL-2-IMIDAZOLES WITH AFFINITY WITH THE TRACE AMINE ASSOCIATED RECEPTORS | F. Hoffmann-Roche AG (CH) | 2009-07-08 | — | — | EP | claimed |
| US-20080096906-A1 | AMINOMETHYL-2-IMIDAZOLES | HOFFMANN-LA ROCHE INC. | 2008-04-24 | — | — | US | claimed |
| WO-2008046756-A1 | AMINOMETHYL-2-IMIDAZOLES WITH AFFINITY WITH THE TRACE AMINE ASSOCIATED RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | claimed |
| CN-101528709-B | Aminomethyl-2-imidazoles with affinity with the trace amine associated receptors | F. HOFFMANN-LA ROCHE AG (CH) | 2012-02-01 | — | — | CN | disclosed |
| EP-2076496-B1 | AMINOMETHYL-2-IMIDAZOLES WITH AFFINITY WITH THE TRACE AMINE ASSOCIATED RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-03-31 | — | — | EP | disclosed |
| CN-101528709-A | Aminomethyl-2-imidazoles with affinity with the trace amine associated receptors | HOFFMANN LA ROCHE (CH) | 2009-09-09 | — | — | CN | disclosed |
| EP-1601966-B1 | METHODS AND COMPOSITIONS FOR PURIFICATION OF NUCLEIC ACID FROM A HOST CELL | QIAGEN NORTH AMERICAN HOLDINGS (US) | 2009-04-29 | — | — | EP | disclosed |
| US-20080096906-A1 | AMINOMETHYL-2-IMIDAZOLES | HOFFMANN-LA ROCHE INC. | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096906-A1 | AMINOMETHYL-2-IMIDAZOLES | HTR2C, AHR, HAX1 | TAAR1 60/4885TSHR 602/4885CYP2D6 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.